# Checklist: controlled substance prescribing by telemedicine before the DEA flexibilities end on December 31, 2026

Twelve steps for health systems, telehealth groups and their prescribers under 21 CFR 1307.41: who relies on the temporary rule, the four conditions it sets, the pathways that remain after it expires, the buprenorphine rule in 21 CFR 1306.51, and what to watch.

Checklist · Healthcare · Operations & Workforce. Published November 14, 2026. Last reviewed November 14, 2026.

## Where the temporary rule stands

Section 1307.41 of the DEA’s regulations lets a DEA-registered practitioner prescribe schedule II to V controlled substances by telemedicine to a patient they have not evaluated in person, if four conditions are met. The current eCFR text, up to date as of November 12, 2026, says the authorization in the section expires at the end of December 31, 2026, and that it covers the period May 12, 2023, through December 31, 2026 [1]. The DEA and HHS issued this fourth temporary extension in a rule published on December 31, 2025 (90 FR 61301), effective January 1, 2026 through December 31, 2026 [2]. As checked on November 14, 2026, section 1307.41 still ends on December 31, 2026, special registrations remain at the proposal stage published on January 17, 2025, and a Federal Register search on 2026-11-14 found no later document extending the section or finalizing special registrations [1] [6]. Our [explainer](https://insights.moraph.com/medicare-telehealth-and-dea-telemedicine-flexibilities-explained) sets out the background.

## Using the steps

Steps 1 to 4 check prescribing under the temporary rule today; steps 5 to 7 plan for the day after it ends; steps 8 to 11 cover the buprenorphine and Veterans Affairs rules already in part 1306 [3]; step 12 covers monitoring and communication. Each step cites the text it rests on, and where a step is our suggestion, it says so. The owner under each step is a typical role; the rules place the duties on the practitioner, and on the pharmacist where step 10 says so. State law on telehealth and prescribing also applies and is outside this checklist. This page explains the rules; it is not legal advice or clinical guidance, and organizations should ask counsel how they apply to their prescribers and patients.

Moraph’s teams help organizations with work like this. [See our solutions](https://www.moraph.com/solutions).

## The checklist

1. **List every patient whose controlled substance prescriptions rest on section 1307.41, meaning the prescriber has not evaluated the patient in person.** (Telehealth program director with pharmacy informatics) Section 1307.41(b) authorizes prescribing without an in-person medical evaluation only during the period May 12, 2023, through December 31, 2026, and section 1307.41(a) says the authorization expires at the end of December 31, 2026 [1]. The fourth extension rule states it is effective January 1, 2026 through December 31, 2026 [2]. Building the list from prescribing and visit records is our suggestion; the rule does not require a list.
2. **Check that each prescription under the temporary rule meets all four conditions in section 1307.41(c).** (Medical director for telehealth) The prescription must be issued for a legitimate medical purpose in the usual course of professional practice; through an interactive telecommunications system referred to in 42 CFR 410.78(a)(3); by a practitioner authorized under their registration to prescribe that basic class of controlled substance, or exempt from registration under 21 U.S.C. 822(d); and consistently with all other requirements of part 1306 [1].
3. **Confirm the platform and scheduling rules use audio and video, and use audio-only only where the definition allows it.** (Virtual care operations lead) Section 1307.41(c)(2) refers to the interactive telecommunications system in 42 CFR 410.78(a)(3) [1]. That definition requires, at a minimum, audio and video equipment permitting two-way, real-time interactive communication. It also allows two-way, real-time audio-only communication for services to a patient in their home if the distant site practitioner is technically capable of video but the patient is not capable of, or does not consent to, video [5]. Recording in the visit note why an encounter was audio-only is our suggestion.
4. **Check each prescriber’s DEA registration covers the schedules they prescribe, and track registration expiry dates.** (Medical staff office) Section 1307.41(c)(3) requires the practitioner to be authorized under their registration under 21 CFR 1301.13(e)(1)(iv) to prescribe the basic class of controlled substance on the prescription, or to be exempt under 21 U.S.C. 822(d) [1]. Tracking expiry dates centrally is our suggestion.
5. **For patients who will need continued treatment, plan in-person evaluations before the temporary rule ends, unless another pathway in steps 6 to 8 applies.** (Clinic operations managers) The DEA’s 2025 proposed rule on special registrations states that the Ryan Haight Act generally requires an in-person medical evaluation before a controlled substance prescription, with an exception for the practice of telemedicine as the Act defines it [6]. Section 1307.41(a) says the authorization expires at the end of December 31, 2026 [1]. Scheduling visits by priority and capacity is our suggestion.
6. **Map which forms of the practice of telemedicine in 21 CFR 1300.04(i) the organization can use once the temporary rule ends.** (Compliance officer with the telehealth program director) Section 1300.04(i) defines the practice of telemedicine through seven categories: treatment while the patient is in a registered hospital or clinic; treatment while the patient is in the physical presence of a registered practitioner; the Indian Health Service or a tribal organization; a public health emergency declared by the HHS Secretary with designations made with the DEA Administrator’s concurrence; a special registration under 21 U.S.C. 831(h); a Department of Veterans Affairs medical emergency; and other circumstances specified by regulation [4]. The first two generally require registration in the state where the patient is located [4].
7. **For each patient group, decide which pathway applies after December 31, 2026 and record the decision.** (Medical director for telehealth) Once section 1307.41 expires, the authorization in section 1307.41(b) ends [1], and the remaining routes are those in section 1300.04(i) and part 1306 [4] [3]. Recording a pathway for each group, and who reviewed it, is our suggestion.
8. **Where buprenorphine or another schedule III to V medication approved for opioid use disorder is prescribed by telemedicine, apply section 1306.51 and its six-month limit.** (Addiction medicine lead) Section 1306.51(b) allows a prescription for schedule III to V controlled substances approved by the FDA for treating opioid use disorder through an interactive telecommunications system, including audio-only, as described in 42 CFR 410.78(a)(3). Under section 1306.51(b)(2), prescriptions under the section may run for no more than six calendar months from the date the first one is issued; after that, the practitioner needs at least one in-person medical evaluation or another authorization under 21 U.S.C. 829(e) [3]. The DEA and HHS delayed the effective date of this rule to December 31, 2025 [7], and the section appears in the current eCFR text [3].
9. **Build the PDMP review into the prescribing workflow for section 1306.51 prescriptions, with the date and time recorded, and a fallback when the PDMP is down.** (EHR and pharmacy informatics team) Section 1306.51(b)(1) requires the prescriber to review PDMP data from the state where the patient is located for the last year, or the whole period if less is available, before prescribing, and to annotate the date and time of the review in the patient’s record. Under section 1306.51(b)(3), if the PDMP is unavailable the prescriber annotates the attempt and the reason, may prescribe a seven-day supply, and must review again before the next seven-day supply; those supplies count toward the six-month limit [3]. Prompting the annotation in the EHR is our suggestion.
10. **Tell the organization’s pharmacies to verify the patient’s identity before filling a section 1306.51 prescription.** (Director of pharmacy) Section 1306.51(b)(4) requires the pharmacist to verify the patient’s identity with a state or federal government-issued photographic identification card or other form of identification before filling, and allows identification from a qualifying ultimate user [3].
11. **If the organization’s practitioners prescribe as employees or contractors of the Department of Veterans Affairs, check that prescribing against section 1306.52.** (VA program lead or compliance officer) Section 1306.52 allows a VA employee or contractor acting in the scope of that employment or contract to prescribe by telemedicine to a VA patient who has previously had an in-person medical evaluation by any VA practitioner, but not for a contracted practitioner outside a VA facility providing care through the community care network or doing disability compensation evaluations. Before prescribing, the practitioner reviews the VA record and the PDMP of the state where the patient is located for the previous twelve months, limits the prescription to a 7-day supply if either is unavailable, and annotates the attempts [3].
12. **Watch the Federal Register for another extension or a special registration final rule, and tell patients and prescribers what changes before the end of the year.** (Compliance officer with patient communications) The DEA proposed special registrations for telemedicine on January 17, 2025, with comments due on or before March 18, 2025 [6]. As checked on November 14, 2026, the eCFR text still ends section 1307.41 on December 31, 2026 [1], and a Federal Register search on 2026-11-14 found no later document finalizing special registrations or extending the section beyond the fourth extension [2]. Writing to affected patients in good time is our suggestion; neither rule requires a patient notice.

## Sources

1. Electronic Code of Federal Regulations. 21 CFR 1307.41, Temporary extension of certain COVID-19 telemedicine flexibilities for prescription of controlled medications, current text up to date as of November 12, 2026. <https://www.ecfr.gov/current/title-21/section-1307.41> Checked November 14, 2026.
2. Drug Enforcement Administration and Department of Health and Human Services (Office of the Federal Register). Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, 90 FR 61301 (December 31, 2025). <https://www.federalregister.gov/documents/2025/12/31/2025-24123/fourth-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled> Checked November 14, 2026.
3. Electronic Code of Federal Regulations. 21 CFR part 1306, Prescriptions, including sections 1306.51 and 1306.52, current text up to date as of November 12, 2026. <https://www.ecfr.gov/current/title-21/chapter-II/part-1306> Checked November 14, 2026.
4. Electronic Code of Federal Regulations. 21 CFR 1300.04, Definitions relating to the dispensing of controlled substances by means of the Internet, current text up to date as of November 12, 2026. <https://www.ecfr.gov/current/title-21/section-1300.04> Checked November 14, 2026.
5. Electronic Code of Federal Regulations. 42 CFR 410.78, Telehealth services, paragraph (a)(3), current text up to date as of November 12, 2026. <https://www.ecfr.gov/current/title-42/section-410.78> Checked November 14, 2026.
6. Drug Enforcement Administration (Office of the Federal Register). Special Registrations for Telemedicine and Limited State Telemedicine Registrations, proposed rule, 90 FR 6541 (January 17, 2025). <https://www.federalregister.gov/documents/2025/01/17/2025-01099/special-registrations-for-telemedicine-and-limited-state-telemedicine-registrations> Checked November 14, 2026.
7. Drug Enforcement Administration and Department of Health and Human Services (Office of the Federal Register). Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, delay of effective dates, 90 FR 13410 (March 24, 2025). <https://www.federalregister.gov/documents/2025/03/24/2025-05007/expansion-of-buprenorphine-treatment-via-telemedicine-encounter-and-continuity-of-care-via> Checked November 14, 2026.

Published: November 14, 2026
Canonical URL: <https://insights.moraph.com/checklist-dea-telemedicine-controlled-substance-prescribing-after-2026>
Publisher: Moraph Insights
